Bavarian Nordic Crecimiento futuro

Future controles de criterios 1/6

Se prevé que los ingresos de Bavarian Nordic disminuyan en un 1.9% al año, mientras que se espera que sus beneficios anuales crezcan en un 5.9% al año. Se prevé que el BPA disminuya en un 0.6% anual. Se prevé que la rentabilidad financiera sea de 7.8% en 3 años.

Información clave

5.7%

Tasa de crecimiento de los beneficios

-0.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	26.6%
Tasa de crecimiento de los ingresos	-2.0%
Rentabilidad financiera futura	7.8%
Cobertura de analistas	Low
Última actualización	10 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BATS-CHIXE:BAVAC - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,202	923	1,737	1,768	3
12/31/2025	5,084	935	1,680	1,831	5
12/31/2024	5,254	778	-38	263	4
3/31/2024	6,642	984	1,028	1,769	N/A
12/31/2023	7,062	1,475	142	1,119	N/A
9/30/2023	5,906	723	-793	751	N/A
6/30/2023	5,533	1,076	-979	568	N/A
3/31/2023	4,083	301	-1,344	-18	N/A
12/31/2022	3,151	-347	-1,162	220	N/A
9/30/2022	2,404	-599	-1,345	-109	N/A
6/30/2022	1,849	-693	-1,342	-101	N/A
3/31/2022	1,683	-606	-1,477	-215	N/A
12/31/2021	1,898	-465	-1,417	-358	N/A
9/30/2021	1,583	-737	-1,541	-663	N/A
6/30/2021	1,693	-629	-1,279	-478	N/A
3/31/2021	2,022	-368	-727	20	N/A
12/31/2020	1,852	278	-135	572	N/A
9/30/2020	1,914	606	-1,613	981	N/A
6/30/2020	1,499	481	-1,970	623	N/A
3/31/2020	901	267	-2,427	227	N/A
12/31/2019	662	-347	-2,947	-276	N/A
9/30/2019	554	-402	-645	-262	N/A
6/30/2019	631	-271	-529	-204	N/A
3/31/2019	616	-279	-408	-152	N/A
12/31/2018	501	-362	-500	-289	N/A
9/30/2018	360	-445	-647	-467	N/A
6/30/2018	873	-151	-706	-564	N/A
3/31/2018	1,184	5	-258	-158	N/A
12/31/2017	1,370	181	N/A	216	N/A
9/30/2017	1,745	453	N/A	1,030	N/A
6/30/2017	1,463	225	N/A	880	N/A
3/31/2017	1,182	153	N/A	501	N/A
12/31/2016	1,007	31	N/A	268	N/A
9/30/2016	909	-54	N/A	-539	N/A
6/30/2016	536	-202	N/A	-345	N/A
3/31/2016	808	-115	N/A	-561	N/A
12/31/2015	1,021	59	N/A	105	N/A
9/30/2015	1,244	155	N/A	818	N/A
6/30/2015	1,390	186	N/A	815	N/A
3/31/2015	1,166	70	N/A	1,018	N/A
12/31/2014	1,217	26	N/A	339	N/A
9/30/2014	1,013	-99	N/A	-63	N/A
6/30/2014	1,107	-61	N/A	-105	N/A
3/31/2014	1,293	-12	N/A	180	N/A
12/31/2013	1,213	-47	N/A	147	N/A
9/30/2013	1,142	-82	N/A	32	N/A
6/30/2013	1,127	-81	N/A	160	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (5.9% al año) de BAVAC es superior a la tasa de ahorro (1.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (5.9% al año) de BAVAC crezcan menos que el mercado UK (13.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de BAVAC crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos de BAVAC disminuyan en los próximos 3 años (-4.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de BAVAC disminuyan en los próximos 3 años (-4.2% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de BAVAC sea baja dentro de 3 años (7.1%).

Bavarian Nordic Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Recent updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Less than half of directors are independent

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Less than half of directors are independent

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

High number of new directors

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

High number of new directors

Bavarian Nordic A/S announced a financing transaction

Third quarter 2021 earnings released: kr.1.30 loss per share (vs kr.0.50 profit in 3Q 2020)

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

First quarter 2021 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Investor sentiment improved over the past week